This invention relates to treating age-related cognitive im-pairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cog-nitive function in subjects that exhib-it age-related cognitive impairment or are at risk thereof, including, with-out limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive De-cline (ARCD) or Age-Associated Memory Impairment (AAMI).
SYNAPTIC VESICLE PROTEIN 2A INHIBITORS FOR TREATING AGE-RELATED COGNITIVE IMPAIRMENT